Grifols
Manufacturing · Spain · 23,505 Employees
View Company Info for Free
About
Headquarters
152 Avinguda De La Generalitat Sant Cugat Del V...Phone Number
+34 935712200Website
www.grifols.comRevenue
$7.6 BillionStock Symbol
GRFSIndustry
Most Recent Scoops
Who is Grifols
Grifols is becoming increasingly global. A diverse team will remain a key component to our future success. Do you want to know more about one of th e leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world. We are a global healthcare company founded in Barcelona, Spain. Since 1940, we have been committed to improving the health and well-being of people around the world. We are an industry leader in producing plasma-derived medicines for patients around the world. Our business is organized into four divisions: Bioscience, Diagnostic, Hospital and Bio Supplies. We sell our products and services in more than 100 countries and have subsidiaries in 30. We aim to be a global leader in our markets and an industry reference for quality, safety and innovation. Grifols' history of growth demonstrates its capacity to evolve and make a positive impact on society. We take great pride in our ethical approach and work diligently to ensure the safety of our products." At Grifols, we think and act with a long-term, sustainable and responsible perspective at every stage of the value chain. We place donors and patients at the heart of our activities to improve people's well-being."Read more
Popular SearchesGrifols International SAGrifols SAGrifolsBiomat USAGrifols IncSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: GRFSShow moreGrifols Org Chart
Is Grifols your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Grifols has new funding data
Earning: See what the market has to say on Grifols recently announced quarterly report
Check out if Grifols is spiking on competitors!
Product Launch: Get notified when Grifols launches new products
Check if Grifols has recently received funding, and reach out quickly before it becomes old news!
Grifols, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Grifols had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Grifols
Recommended Actions
Reach out to Masked Content who joined Grifols as Masked Content
Find 2 more new buyers
Similar Companies to Grifols
Analyze insights from companies similar to Grifols and make strategic comparisons based on performance, financial data, growth and unique benchmarks.
- Baxter International60,000$15B
- CSL32,698$14.7B
- Biogen7,570$9.7B
- Amgen26,700$29.5B
- Regeneron Pharmaceuticals13,926$13.5B
- Bristol-Myers Squibb34,021$46.5B
- Terumo30,000$5.9B
- BD70,000$19.8B
More similar companies
Compare CEO
How does Víctor Grifols Roura compare against Competing Companies' CEOs?
Víctor Grifols Roura
CEO at Grifols
CEO effectiveness to drive business results
VS.
Olivier Brandicourt
CEO at Sanofi Pasteur
Olivier Brandico...
CEO at Sanofi Pasteur
Paul Perreault
CEO at CSL
Grifols Email Formats
Grifols uses at least 5 email formats with first.last (ex. John.Smith@grifols.com) being used 51% of the time
Grifols Email Formats | Percentage | |
---|---|---|
first.last | John.Smith@grifols.com | 51% |
first.last | John.Smith@external.grifols.com | 1.6% |
first + last | JohnSmith@grifols.com | |
first_last | John_Smith@grifols.com | |
first | John@grifols.com |
Get Verified Emails
Grifols Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Grifols Tech Stack
A closer look at the technologies used by Grifols
Most Recent Scoops
Grifols News & Media
Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has established a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to test investigational ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sulfur mustard exposure. BARDA is part of the Administration for Strategic PreparedneBiopharma Layoffs Roundup - Contract Pharma
Evonik, J&J, Bayer, BMS, and more, to layoff employees in 3Q and 4Q 2024.GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programsSignificant Shareholders Exercise Right to Grifols Board Seat
BARCELONA, Spain--(BUSINESS WIRE)--Significant Grifols shareholders fill a vacant board seat, appointing pharma leader Paul Herendeen to drive value and improve governance.
Frequently Asked Questions Regarding Grifols
Grifols is becoming increasingly global. A diverse team will remain a key component to our future success. Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world. We are a global healthcare company f... Read More